CSIMarket Company Name, Ticker, Customers, else..
 
Entera Bio Ltd   (NASDAQ: ENTX)
Other Ticker:  
 
 
Price: $1.8600 $-0.23 -11.005%
Day's High: $2.067 Week Perf: -12.26 %
Day's Low: $ 1.84 30 Day Perf: -7 %
Volume (M): 52 52 Wk High: $ 2.79
Volume (M$): $ 97 52 Wk Avg: $1.95
Open: $2.01 52 Wk Low: $1.41



 Market Capitalization (Millions $) 81
 Shares Outstanding (Millions) 43
 Employees 31
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) 10
 Cash Flow (TTM) (Millions $) 10
 Capital Exp. (TTM) (Millions $) 0

Entera Bio Ltd
Entera Bio Ltd is a biotechnology company that specializes in oral delivery of large molecule drugs and biologics. They develop and commercialize oral formulations of drugs typically administered by injection, with the aim of improving patient outcomes and convenience. The company utilizes a proprietary oral protein delivery platform to develop these formulations. Their technology involves encapsulating the drugs in a protective delivery vehicle, allowing them to survive the harsh conditions of the gastrointestinal tract and be effectively absorbed into the bloodstream. Entera Bio is focused on developing therapies for various diseases, including osteoporosis, hypoparathyroidism, and inflammatory bowel disease. Their mission is to revolutionize drug delivery by enabling patients to take important medications orally, thus eliminating the need for injections.


   Company Address: Kiryat Hadassah Jerusalem 9112002
   Company Phone Number: 2-532-7151   Stock Exchange / Ticker: NASDAQ ENTX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN        1.81% 
BIIB   -2.61%    
CHRS   -10.85%    
EXEL   -3.1%    
GILD   -2.67%    
HALO   -0.74%    
• View Complete Report
   



Product Service News

Pioneering Oral Peptide Therapy Entera Bio and OPKO Health Announce Significant PK/PD Advancements for Oxyntomodulin ...

Published Wed, Sep 25 2024 12:30 PM UTC

Emerging Innovations in Obesity Treatment: Entera Bio and OPKO Health Announce Promising PK/PD Data for Oral Oxyntomodulin Tablet In a novel collaboration, Entera Bio Ltd. (NASDAQ: ENTX) and OPKO Health, Inc. (NASDAQ: OPK) have revealed encouraging topline pharmacokinetic (PK) and pharmacodynamic (PD) outcomes for their oral oxyntomodulin (OXM) tablet candidate. This innova...
Clinical Study

Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates

Published Fri, Aug 9 2024 8:05 PM UTC

Entera Bio Ltd. Reports Q2 2024 Financial Results and Notable Business Updates Entera Bio Ltd. (NASDAQ: ENTX), a frontrunner in the development of orally delivered peptides and small therapeutic proteins, has recently released its financial results for the second quarter of 2024. Additionally, the company has achieved critical milestones in the development of its lead clini...
Management Changes

Dr. Rachel B Wagman: Pioneering Oral Drug Delivery with Entera Bio

Published Wed, May 15 2024 12:01 PM UTC

Introducing Dr. Rachel B Wagman: A Leading Clinical Advisor Joins Entera Bio s Scientific Advisory Board
JERUSALEM, May 15, 2024 - Entera Bio Ltd. (NASDAQ: ENTX), a pioneering company in the development of orally delivered peptides and small therapeutic proteins, has recently announced the appointment of Dr. Rachel B Wagman, MD, FACE, FACP, as their Key Clinical Advisor ...
Clinical Study

Entera Bio Spotlights the Promising Phase 1 Data of EB612 Oral Peptide Tablets for Hypoparathyroidism at ENDO 2024

Published Mon, May 13 2024 11:00 AM UTC

Entera Bio Ltd., a renowned pioneer in the research and development of orally delivered peptides and minor therapeutic proteins, has recently announced that it will present the promising data from the Phase 1 study of PTH(1-34) Peptide Tablets (EB612) an innovative first-in-class treatment for hypoparathyroidism at the prestigious Endocrine Society s Annual Meeting, ENDO...
Entera Bio Ltd

Entera Bio Ltd Achieves New Milestone with Operating Profit Announcement

Entera Bio Ltd. (NASDAQ: ENTX), a prominent leader in the development of orally delivered peptides and small therapeutic proteins, recently announced the successful results of its Phase 2 clinical trial for EB613, an investigational compound. This breakthrough was published in the esteemed Journal of Bone and Mineral Research, further solidifying Entera's position as a pioneer in the industry.
The Phase 2 trials for EB613 showcased significant efficacy in treating Post-Menopausal Women with Low Bone Mineral Density (BMD) or Osteoporosis. This achievement marks a momentous milestone for Entera, as it takes a significant step towards addressing the critical unmet need in the treatment of Osteoporosis, a prevalent health issue affecting millions of women post-menopause. This development also presents a colossal market opportunity as the world grapples with the impact of physiological disorders on quality of life.






Entera Bio Ltd's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com